THE OUTPATIENT BASED REGISTRY RECVASA: PROSPECTIVE FOLLOW-UP DATA, RISK EVLUATION AND OUTCOMES IN CARDIOVASCULAR PATIENTS

Aim. To evaluate, under the frame of prospective registry, the 12-month outcomes and risks in patients with arterial hypertension (AH), ischemic heart disease (CHD), chronic heart failure (CHF) and atrial fibrillation (AF) in the real outpatient practice in Ryazan Region. Material and methods. Into...

Full description

Saved in:
Bibliographic Details
Main Authors: S. A. Boytsov, М. М. Lukyanov, S. S. Yakushin, S. Yu. Martsevich, A. N. Vorobyev, A. V. Zagrebelny, K. G. Pereverzeva, Е. А. Pravkina, A. D. Deev, E. Yu. Andreenko, A. I. Ershova, A. N. Meshkov, R. P. Myasnikov, S. S. Serdyuk, M. S. Kharlap, E. V. Bazaeva, A. N. Kozminsky, K. A. Moseychuk, V. G. Klyashtorny, E. V. Kudryashov
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2015-02-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/119
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849408542742675456
author S. A. Boytsov
М. М. Lukyanov
S. S. Yakushin
S. Yu. Martsevich
A. N. Vorobyev
A. V. Zagrebelny
K. G. Pereverzeva
Е. А. Pravkina
A. D. Deev
E. Yu. Andreenko
A. I. Ershova
A. N. Meshkov
R. P. Myasnikov
S. S. Serdyuk
M. S. Kharlap
E. V. Bazaeva
A. N. Kozminsky
K. A. Moseychuk
V. G. Klyashtorny
E. V. Kudryashov
author_facet S. A. Boytsov
М. М. Lukyanov
S. S. Yakushin
S. Yu. Martsevich
A. N. Vorobyev
A. V. Zagrebelny
K. G. Pereverzeva
Е. А. Pravkina
A. D. Deev
E. Yu. Andreenko
A. I. Ershova
A. N. Meshkov
R. P. Myasnikov
S. S. Serdyuk
M. S. Kharlap
E. V. Bazaeva
A. N. Kozminsky
K. A. Moseychuk
V. G. Klyashtorny
E. V. Kudryashov
author_sort S. A. Boytsov
collection DOAJ
description Aim. To evaluate, under the frame of prospective registry, the 12-month outcomes and risks in patients with arterial hypertension (AH), ischemic heart disease (CHD), chronic heart failure (CHF) and atrial fibrillation (AF) in the real outpatient practice in Ryazan Region. Material and methods. Into the outpatient registry RECVASA (REgistry of CardioVAScular diseases) totally 3690 patients included with AH, CHD, CHF, AF and their comorbidity, visited 3 outpatient institutions in Ryzan city: 1047 (28%) of men and 2643 women, mean age 66,1±12,9 y.o. The estimation of 12-mint risk of events fter inclusion in registry RECVASA was done for 3619 (98,1%) participants. Results. By 12 month after inclusion 168 patients (4,6%) died, had stroke (S) — 62 (1,7%), myocardial infarction (MI) — 26 (0,7%), cardiovascular surgery (CVS) — 6 (0,2%). Totally 235 hospitalizations for CVD registered. The risk of death, MI development and S had been increasing by 5-9% every year of patient age, and CVD hospitalization — decreased by 2%. Combined death risk and cardiovascular death risk were significantly higher (1,3-6,4 times) with anamnesis of MI, S, diabetes mellitus (DM), chronic obstructive lung disease (COPD), CHF of 3-4 functional class (FC), in males and with blood pressure (BP) <110/75 mmHg, heart rate (HR) >90 bpm, glomerular filtration rate (GFR) <45 ml/min. Higher MI risk (1,8-3,4 times) was linked to the anamnesis of diabetes and MI, angina pectoris (FC 3-4) and GFR <45 ml/min. MI risk was higher by 2,4-7,2 times in patients with anamnesis of MI, permanent AF, and with combinations of AH, CHD, CHF and AF, with BP <110/75 mmHg and >180/110 mmHg, HR >90/min. Risk of all-cause death was lower in those who received p-adrenoblockers, angiotensin-converting enzyme inhibitors (iACE) and angiotensin receptor blockers (ARB) 1,4-1,5 times, death from cardiovascular causes — with iACE and ARB — 2 times lower. Patients on p-blockers had 1,8 times lower risk of MI. Conclusion. Prospective follow-up of cardiovascular patients under the frame of RECVASA registry showed significant negative influence on prognosis the following: age, male gender, anamnesis of MI and S, DM, COPD, CHF (3-4 FC), angina (3-4 FC), permanent AF, BP <110/75 and >180/110 mmHg, GFR <45 ml/min, HR >90/min, combination of AH, CHD, CHF and AH, CHD, CHF, AF. Positive influence on prognosis with CVD had treatment with p-adrenoblockers, iACE, ARB.
format Article
id doaj-art-39bf6cc48a474ce989494a63d24c741e
institution Kabale University
issn 1728-8800
2619-0125
language Russian
publishDate 2015-02-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj-art-39bf6cc48a474ce989494a63d24c741e2025-08-20T03:35:45Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252015-02-01141536210.15829/1728-8800-2015-1-53-62119THE OUTPATIENT BASED REGISTRY RECVASA: PROSPECTIVE FOLLOW-UP DATA, RISK EVLUATION AND OUTCOMES IN CARDIOVASCULAR PATIENTSS. A. Boytsov0М. М. Lukyanov1S. S. Yakushin2S. Yu. Martsevich3A. N. Vorobyev4A. V. Zagrebelny5K. G. Pereverzeva6Е. А. Pravkina7A. D. Deev8E. Yu. Andreenko9A. I. Ershova10A. N. Meshkov11R. P. Myasnikov12S. S. Serdyuk13M. S. Kharlap14E. V. Bazaeva15A. N. Kozminsky16K. A. Moseychuk17V. G. Klyashtorny18E. V. Kudryashov19State Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowRyazan State Medical University n.a. I. P. Pavlov. Ryazan, RussiaState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowRyazan State Medical University n.a. I. P. Pavlov. Ryazan, RussiaState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowRyazan State Medical University n.a. I. P. Pavlov. Ryazan, RussiaRyazan State Medical University n.a. I. P. Pavlov. Ryazan, RussiaState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowRyazan State Medical University n.a. I. P. Pavlov. Ryazan, RussiaRyazan State Medical University n.a. I. P. Pavlov. Ryazan, RussiaState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowState Scientific-Research Center of Preventive Medicine of the Ministry of Healthcare. MoscowAim. To evaluate, under the frame of prospective registry, the 12-month outcomes and risks in patients with arterial hypertension (AH), ischemic heart disease (CHD), chronic heart failure (CHF) and atrial fibrillation (AF) in the real outpatient practice in Ryazan Region. Material and methods. Into the outpatient registry RECVASA (REgistry of CardioVAScular diseases) totally 3690 patients included with AH, CHD, CHF, AF and their comorbidity, visited 3 outpatient institutions in Ryzan city: 1047 (28%) of men and 2643 women, mean age 66,1±12,9 y.o. The estimation of 12-mint risk of events fter inclusion in registry RECVASA was done for 3619 (98,1%) participants. Results. By 12 month after inclusion 168 patients (4,6%) died, had stroke (S) — 62 (1,7%), myocardial infarction (MI) — 26 (0,7%), cardiovascular surgery (CVS) — 6 (0,2%). Totally 235 hospitalizations for CVD registered. The risk of death, MI development and S had been increasing by 5-9% every year of patient age, and CVD hospitalization — decreased by 2%. Combined death risk and cardiovascular death risk were significantly higher (1,3-6,4 times) with anamnesis of MI, S, diabetes mellitus (DM), chronic obstructive lung disease (COPD), CHF of 3-4 functional class (FC), in males and with blood pressure (BP) <110/75 mmHg, heart rate (HR) >90 bpm, glomerular filtration rate (GFR) <45 ml/min. Higher MI risk (1,8-3,4 times) was linked to the anamnesis of diabetes and MI, angina pectoris (FC 3-4) and GFR <45 ml/min. MI risk was higher by 2,4-7,2 times in patients with anamnesis of MI, permanent AF, and with combinations of AH, CHD, CHF and AF, with BP <110/75 mmHg and >180/110 mmHg, HR >90/min. Risk of all-cause death was lower in those who received p-adrenoblockers, angiotensin-converting enzyme inhibitors (iACE) and angiotensin receptor blockers (ARB) 1,4-1,5 times, death from cardiovascular causes — with iACE and ARB — 2 times lower. Patients on p-blockers had 1,8 times lower risk of MI. Conclusion. Prospective follow-up of cardiovascular patients under the frame of RECVASA registry showed significant negative influence on prognosis the following: age, male gender, anamnesis of MI and S, DM, COPD, CHF (3-4 FC), angina (3-4 FC), permanent AF, BP <110/75 and >180/110 mmHg, GFR <45 ml/min, HR >90/min, combination of AH, CHD, CHF and AH, CHD, CHF, AF. Positive influence on prognosis with CVD had treatment with p-adrenoblockers, iACE, ARB.https://cardiovascular.elpub.ru/jour/article/view/119registrycardiovascular diseasesprospective follow-upprisk factorsoutcomesoutpatient practicecombined cardiovascular pathologycomorbidity
spellingShingle S. A. Boytsov
М. М. Lukyanov
S. S. Yakushin
S. Yu. Martsevich
A. N. Vorobyev
A. V. Zagrebelny
K. G. Pereverzeva
Е. А. Pravkina
A. D. Deev
E. Yu. Andreenko
A. I. Ershova
A. N. Meshkov
R. P. Myasnikov
S. S. Serdyuk
M. S. Kharlap
E. V. Bazaeva
A. N. Kozminsky
K. A. Moseychuk
V. G. Klyashtorny
E. V. Kudryashov
THE OUTPATIENT BASED REGISTRY RECVASA: PROSPECTIVE FOLLOW-UP DATA, RISK EVLUATION AND OUTCOMES IN CARDIOVASCULAR PATIENTS
Кардиоваскулярная терапия и профилактика
registry
cardiovascular diseases
prospective follow-upp
risk factors
outcomes
outpatient practice
combined cardiovascular pathology
comorbidity
title THE OUTPATIENT BASED REGISTRY RECVASA: PROSPECTIVE FOLLOW-UP DATA, RISK EVLUATION AND OUTCOMES IN CARDIOVASCULAR PATIENTS
title_full THE OUTPATIENT BASED REGISTRY RECVASA: PROSPECTIVE FOLLOW-UP DATA, RISK EVLUATION AND OUTCOMES IN CARDIOVASCULAR PATIENTS
title_fullStr THE OUTPATIENT BASED REGISTRY RECVASA: PROSPECTIVE FOLLOW-UP DATA, RISK EVLUATION AND OUTCOMES IN CARDIOVASCULAR PATIENTS
title_full_unstemmed THE OUTPATIENT BASED REGISTRY RECVASA: PROSPECTIVE FOLLOW-UP DATA, RISK EVLUATION AND OUTCOMES IN CARDIOVASCULAR PATIENTS
title_short THE OUTPATIENT BASED REGISTRY RECVASA: PROSPECTIVE FOLLOW-UP DATA, RISK EVLUATION AND OUTCOMES IN CARDIOVASCULAR PATIENTS
title_sort outpatient based registry recvasa prospective follow up data risk evluation and outcomes in cardiovascular patients
topic registry
cardiovascular diseases
prospective follow-upp
risk factors
outcomes
outpatient practice
combined cardiovascular pathology
comorbidity
url https://cardiovascular.elpub.ru/jour/article/view/119
work_keys_str_mv AT saboytsov theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT mmlukyanov theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT ssyakushin theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT syumartsevich theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT anvorobyev theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT avzagrebelny theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT kgpereverzeva theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT eapravkina theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT addeev theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT eyuandreenko theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT aiershova theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT anmeshkov theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT rpmyasnikov theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT ssserdyuk theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT mskharlap theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT evbazaeva theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT ankozminsky theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT kamoseychuk theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT vgklyashtorny theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT evkudryashov theoutpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT saboytsov outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT mmlukyanov outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT ssyakushin outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT syumartsevich outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT anvorobyev outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT avzagrebelny outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT kgpereverzeva outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT eapravkina outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT addeev outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT eyuandreenko outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT aiershova outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT anmeshkov outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT rpmyasnikov outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT ssserdyuk outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT mskharlap outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT evbazaeva outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT ankozminsky outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT kamoseychuk outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT vgklyashtorny outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients
AT evkudryashov outpatientbasedregistryrecvasaprospectivefollowupdatariskevluationandoutcomesincardiovascularpatients